Dr Nicholas Silvestri looks ahead to new data on existing agents and emerging therapies for myasthenia gravis.

Important research news last week included UK pharma major AstraZeneca releasing encouraging results from the CALYPSO Phase ...

Immunovant (NASDAQ:IMVT – Free Report) had its price objective decreased by Bank of America from $38.00 to $33.00 in a ...

Immunovant (NASDAQ:IMVT – Get Free Report)‘s stock had its “buy” rating restated by equities researchers at HC Wainwright in ...

Immunovant IMVT announced top-line data from a late-stage study of its investigational candidate, batoclimab, for myasthenia gravis (MG) and initial results from Period 1 of a mid-stage study of the ...

Immunovant, Inc. had positive results for batoclimab in trials for Myasthenia Gravis & CIDP; Thyroid Eye Disease data ...

The pivotal Phase III study in myasthenia gravis met its primary endpoint with meaningful improvements in MG-ADL across both higher and lower dose arms.

Immunovant, Inc. (NASDAQ:IMVT) released topline results from its Phase 3 study of batoclimab in myasthenia gravis (MG) and ...

Immunovant will use results from its Phase III myasthenia gravis study to support pipeline candidate IMVT-1402 over the trial ...

Analysts were happy with batoclimab’s performance in the chronic autoimmune disorder, but Immunovant said it will continue to ...

Immunovant's experimental drug to treat a type of chronic muscle weakness improved patients' ability to perform daily tasks, but fell short of the effectiveness set by already approved treatments. The ...

Immunovant (Nasdaq: IMVT), a Roivant Sciences company, today reported top-line results from its Phase III study of batoclimab ...